Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma

Lefu Huang, Jingjing Li, Junfang Yang, Xian Zhang, Min Zhang, Jiujiang He, Gailing Zhang, Wenqian Li, Hui Wang, Jianqiang Li, Peihua LuCells 2022 · DOI

TL;DR

This study investigated a novel CAR T-cell therapy targeting both CD19 and CD22 antigens for relapsed/refractory B-cell lymphomas, aiming to overcome antigen escape and improve patient outcomes. The research found that a humanized version of this dual-target CAR T-cell cocktail demonstrated superior efficacy and durability compared to its murinized counterpart, offering a promising advancement in treating aggressive B-cell lymphomas.

What Problem Does This Paper Address?

Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of B-cell hematological malignancies, achieving remarkable response rates. However, a significant challenge remains: relapse due to the tumor's ability to evade therapy by losing the target antigen (e.g., CD19). This "antigen escape" is a major hurdle for long-term remission. To combat this, researchers are exploring strategies to target multiple antigens simultaneously. This paper addresses the need for more robust CAR T-cell therapies by investigating a dual-target approach (CD19 and CD22) and comparing the efficacy and safety of humanized versus murinized versions of this therapy in patients with aggressive B-cell lymphomas that have relapsed or are refractory to standard treatments.

Methods

The study employed a phase I/II clinical trial design to evaluate the safety and efficacy of a CD19 and CD22 CAR T-cell cocktail. Key methodological aspects include:

  • Dual-Target CAR T-cell Construction: The researchers developed both murinized and humanized CAR T-cell constructs targeting CD19 and CD22. The humanized version aimed to reduce immunogenicity by replacing murine single-chain variable fragments (scFvs) with fully human ones.
  • Cocktail Therapy: Patients received a mixed infusion of CD19 and CD22 CAR T-cells.
  • Patient Cohorts: Two groups of patients with relapsed/refractory aggressive B-cell lymphoma were compared: one receiving the murinized CAR19/22 T-cell cocktail and another receiving the humanized CAR19/22 T-cell cocktail.
  • Efficacy and Safety Assessments: Patients were monitored using PET/CT scans and bone marrow evaluations to assess response rates (Complete Response - CR, Partial Response - PR, Stable Disease - SD, Progressive Disease - PD). Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) were graded according to established criteria.
  • Survival Analysis: Progression-Free Survival (PFS) and Overall Survival (OS) were evaluated.
  • CAR T-cell Persistence: Quantitative PCR (qPCR) and flow cytometry were used to track the presence and proliferation of CAR T-cells in peripheral blood.
  • Biomarker Analysis: Cytokine levels in patient serum were measured to correlate with adverse events like CRS.

Datasets

Not discussed in the paper. The study involved a clinical trial with patient data collected prospectively.

Key Insights and Ideas

  • Dual-Targeting as a Strategy: Targeting both CD19 and CD22 is a viable strategy to overcome antigen escape, a common mechanism of relapse in CAR T-cell therapy.
  • Humanization Matters: The humanized CAR T-cell construct demonstrated significantly better efficacy and durability compared to the murinized version, suggesting that reducing immunogenicity is crucial for long-term CAR T-cell function.
  • TP53 Mutation as a Prognostic Factor: Patients with TP53 mutations, a known high-risk factor, showed a trend towards better outcomes with the humanized CAR T-cell therapy, highlighting its potential in challenging patient populations.
  • CAR T-cell Persistence and Efficacy: The humanized CAR T-cells showed a trend towards longer persistence, which correlated with improved PFS, underscoring the importance of sustained CAR T-cell presence for durable responses.
  • Manageable Safety Profile: The CAR19/22 cocktail therapy, in both humanized and murinized forms, was generally well-tolerated, with most adverse events being mild and reversible.

Key Results

  • Efficacy (Day 28):
    • Humanized group: 91.7% objective response rate (ORR), 75% complete response (CR) rate.
  • Murinized group: 92.9% ORR, 42.9% CR rate.
  • Durability (Month 3):
    • Humanized group: 75% maintained CR.
  • Murinized group: 35.7% maintained CR.
  • Survival: Progression-Free Survival (PFS) was more favorable in the humanized group. Overall Survival (OS) did not show a significant difference between groups, potentially due to subsequent therapies.
  • Safety: Most patients experienced mild CRS (grade 1-2). Two patients in the humanized group and two in the murinized group experienced grade 3 CRS. Two patients in the murinized group had grade 3 ICANS, while none in the humanized group did.
  • CAR T-cell Persistence: Humanized CAR T-cells showed a trend towards longer persistence in peripheral blood.

Limitations and Future Work

  • Study Size: The study was not a randomized trial, and the sample size, particularly for subgroup analyses (e.g., TP53 mutations), was limited. This limits the statistical power to draw definitive conclusions.
  • Subsequent Therapies: The impact of subsequent treatments on overall survival makes it difficult to isolate the CAR T-cell therapy's effect on OS.
  • Future Directions: The authors emphasize the need for larger, randomized controlled studies to confirm these findings. Further research is also suggested to explore the role of regulatory T-cells (Tregs) in the context of CAR T-cell immunogenicity and persistence, and to investigate strategies for prolonging CAR T-cell persistence in vivo.

Summary updated

Abstract

CD19 chimeric antigen receptor T-cell (CAR-T) therapy is efficacious for refractory/relapsed (R/R) B-cell hematological malignancies, yet relapse due to CD19 antigen escape remains a challenge. Our trial explored simultaneous targeting of multiple B-cell antigens as a therapeutic approach that may reduce the risk of relapse. We tested the safety and efficacy of CAR19/22 T-cell cocktail therapy including murinized and humanized products among patients with R/R aggressive B-cell lymphoma. In the group that received the humanized product, 11/12 (91.7%) patients achieved an objective response, including 9/12 (75%) complete responses (CRs) by day 28. The overall response rate and CR rate in the murinized group was 92.9% (13/14) and 42.9% (6/14), respectively. Nine of 12 (75%) patients in the humanized group maintained CR at month 3 following infusion, compared to 5/14 patients (35.7%) in the murinized group. Progression-free survival (PFS) was more favorable in the humanized compared to the murinized group. Most patients had mild cytokine release syndrome (CRS) (grade 1-2) in both groups. This study demonstrates that CAR19/22 T-cell cocktail therapy is safe and effective for R/R B-cell lymphoma and that patients treated with a humanized CAR-T exhibited better efficacy compared to patients treated with a murinized CAR-T therapy.
BibTeX
@inproceedings{huang2022safety,
  author = {Lefu Huang and Jingjing Li and Junfang Yang and Xian Zhang and Min Zhang and Jiujiang He and Gailing Zhang and Wenqian Li and Hui Wang and Jianqiang Li and Peihua Lu and Jianqiang Li and Peihua Lu},
  title = {{Safety and Efficacy of Humanized Versus Murinized CD19 and CD22 CAR T-Cell Cocktail Therapy for Refractory/Relapsed B-Cell Lymphoma}},
  booktitle = {Cells},
  year = {2022},
  doi = {10.3390/cells11244085},
}
Figure